Research programme : anti-cancer and anti-inflammatory therapeutics - Oxcia
Latest Information Update: 05 Sep 2023
At a glance
- Originator Oxcia
- Class Anti-inflammatories; Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer; Inflammation
Most Recent Events
- 05 Sep 2023 Research programme : anti-cancer and anti-inflammatory therapeutics - Oxcia is available for licensing as of 05 Sep 2023. https://oxcia.com/about-us/collaborators/ (Oxcia pipeline, August 2023)
- 23 Aug 2023 Early research in Cancer in Sweden (unspecified route) (Oxcia pipeline, August 2023)
- 23 Aug 2023 Early research in Inflammation in Sweden (unspecified route) (Oxcia pipeline, August 2023)